A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Trial Details

NCT ID
NCT07382739
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • RRMM exposed to IMID, PI, anti-CD38 mAb, relapsed or refractory to at least one prior line of therapy (LOT), progressed on or after the last regimen:
  • Relapsed disease: progressive disease (PD) \>60 days after cessation of prior therapy
  • Refractory disease: PD \<=60 days after cessation of prior therapy, \<25% reduction in paraprotein (monoclonal protein \[M-protein\] or serum free …
  • Diagnosis of relapsed or refractory multiple myeloma as indicated by progression by IMWG criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →